FDA has indicated Moxidectin from Medicines Development for Global Health to treat onchocerciasis (river blindness) resulting from Onchocerca volvulus in patients aged 12 years and older. The drug won that indication in June 2020.
The drug is the first novel treatment for river blindness in two decades.